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Abstract
Background: Hypertriglyceridemia is a common type of dyslipidemia found in obesity. However, it is not established
whether primary hyperlipidemia can predispose to obesity. Evidences have suggested that proteins primarily related to
plasma lipoprotein transport, such as apolipoprotein (apo) CIII and E, may significantly affect the process of body fat
accumulation. We have previously observed an increased adiposity in response to a high fat diet (HFD) in mice
overexpressing apoCIII. Here, we examined the potential mechanisms involved in this exacerbated response of
apoCIII mice to the HFD.
Methods: We measured body energy balance, tissue capacity to store exogenous lipids, lipogenesis and lipolysis
rates in non-transgenic and apoCIII overexpressing mice fed a HFD during two months.
Results: Food intake, fat excretion and whole body CO2 production were similar in both groups. However, the
adipose tissue mass (45 %) and leptin plasma levels (2-fold) were significantly greater in apoCIII mice. Lipogenesis
rates were similar, while exogenous lipid retention was increased in perigonadal (2-fold) and brown adipose tissues
(40 %) of apoCIII mice. In addition, adipocyte basal lipolysis (55 %) and in vivo lipolysis index (30 %) were significantly
decreased in apoCIII mice. A fat tolerance test evidenced delayed plasma triglyceride clearance and greater transient
availability of non-esterified fatty acids (NEFA) during the post-prandial state in the apoCIII mice plasma. Thus, apoCIII
overexpression resulted in increased NEFA availability to adipose uptake and decreased adipocyte lipolysis, favoring
lipid enlargement of adipose depots.
Conclusion: We propose that plasma apoCIII levels represent a new risk factor for diet-induced obesity.
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Background
Obesity is a condition in which excess body fat accumu-
lates and may adversely affect one’s health. Body fat con-
tent is determined by interactions between genetic and
environmental factors acting through the mediators of
energy intake and expenditure [1, 2]. The World Health
Organization estimates that in 2014 approximately 2
billion people around the world were overweight, and
approximately 600 million were obese [3]. Overweight
and obesity are associated with an excess of cardiovas-
cular and non-cardiovascular deaths in the general
population [4, 5].
Hypertriglyceridemia is one of the most common types
of dyslipidemia found in obesity, together with low HDL
levels and the presence of small and dense LDL particles
[6]. Most disorders in lipoprotein metabolism in obese
subjects are considered as consequences of insulin
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resistance [6, 7]. However, it is not established whether
primary hyperlipidemia can predispose one to obesity.
Experimental evidences have suggested that proteins pri-
marily related to plasma lipoprotein transport, such as
apolipoprotein (apo) C and E, may significantly influence
body fat accumulation. Overall, deficiency of apoE re-
sults in diminution of diet-induced obesity [8–12]. Re-
garding apoC, the knockout of apoCIII seems to
exacerbate diet induced obesity [13, 14], while the
overexpression of apoCI protects from diet and genetic
obesity [15].
ApoCIII is mainly found in triglyceride (TG)-rich li-
poproteins [16, 17]. A strong positive correlation be-
tween plasma apoCIII and TG concentrations has been
invariably observed in human and animal studies [18–20].
Transgenic mice overexpressing human apoCIII have
marked elevated TG and non-esterified fatty acid (NEFA)
levels [21]. ApoCIII overexpression in this model increases
the half-life of TG-rich lipoproteins, without changing
lipoprotein lipase (LPL) activity in vivo [22, 23], although
this apolipoprotein may be a potent LPL inhibitor in vitro
[24, 25]. In addition, growing evidence has linked apoCIII
concentrations in plasma lipoproteins, including HDL, to
coronary heart disease [19, 20, 26, 27].
We previously hypothesized that apoCIII overexpres-
sion would compromise fatty acid delivery to adipose
tissues and would thus contribute to resistance to diet-
induced obesity, similarly to what was described for
overexpression of apoCI [15]. However, this was not the
case, as after five months of a high fat diet, apoCIII over-
expressing mice accumulated more body fat than non-
transgenic littermates [28]. Therefore, the role of apoCIII
on adiposity seems to be quite complex because both
apoCIII overexpression or disruption results in more se-
vere diet-induced obesity than wild type mice [14].
Therefore, the aim of the present study was to evaluate
major functional and biochemical processes which could
be involved in diet-induced body fat accumulation re-
lated to the excess of apoCIII.
Methods
Animals and treatments
Human apoCIII transgenic mice (line 3707) [29] foun-
ders were originally donated by Dr. Alan R. Tall
(Columbia University, New York, NY, 1996) and cross-
bred with wild-type (NTg) C57BL/6 J mice. The apoCIII
transgenic colony has been kept since 1996 at the animal
facilities of the Division of Physiology and Biophysics at
the State University of Campinas (São Paulo, Brazil).
The experiments were approved by the university’s eth-
ics committee (protocol # 1607–1). Transgenic mice
were screened according to their triglyceride plasma
levels (apoCIII > 300 mg/dl and controls < 100 mg/dl).
All experiments were performed with female mice.
ApoCIII transgenic and non-transgenic (NTg) female lit-
termates were housed in a room at 22 °C ± 1 °C with a
12-hour light–dark cycle and had free access to water
and diet ad libitum. From weaning, mice received stand-
ard laboratory rodent diet (CR1; Nuvital, Colombo, PR,
Brazil) and a high fat diet (HFD) from 2 to 4 months of
age (Additional file 1) or from 4 to 6 months of age.
Mice body weight and food intake were measured
weekly. At the end of the diet treatment, mice were
anesthetized with ketamine and xylazine (100 and
10 mg/Kg, respectively) and killed by exsanguination
through the retroorbital plexus. The perigonadal, sub-
cutaneous (inguinal) and interscapular brown adipose
tissues were excised and fresh masses were determined
gravimetrically.
Plasma biochemical analyses
The plasma levels of total cholesterol (CHOL), triglycerides
(TG) (Chod-Pap; Roche Diagnostic GmbH, Mannheim,
Germany), non-esterified fatty acids (NEFA) (Wako Chemi-
cals, Neuss, Germany) and glycerol (Bioclin, Quibasa; Belo
Horizonte, Brazil) were determined using enzymatic colori-
metric assays according to the manufacturer's instructions.
Blood glucose (GLUC) concentrations were measured
using a glucose analyzer (Accu-Chek Advantage, Roche
Diagnostic, Switzerland). Leptin plasma concentrations
were determined by ELISA kit (Merck Millipore,
Darmstadt, Germany). A fluorometric assay kit was
used to determine the LPL activity (Cell Biolabs, San
Diego, USA). Analyses were performed either in the
fed state or after 12 h of fasting. Mice were also tested
for glucose tolerance, as follows: fasted mice received
an oral dose of a glucose solution (1.5 g/kg) and
plasma glucose levels were determined at 0, 15, 30, 60,
90 and 120 min. Glycemia was measured with a gluc-
ometer Accu-Chek Advantage (Roche Diagnostic,
Switzerland).
In vivo CO2 production rates
Whole body in vivo CO2 production rates were mea-
sured in a temperature-monitored respirometer, as pre-
viously described [30]. Fed mice were adapted to the
respirometer chamber twice a day for 5 minutes. After
the adaptation period, the CO2 expiration of each mouse
was monitored for 5 minutes once a day, between 9 AM
and 11 AM, for 5 consecutive days. CO2 production
rates were calculated as the average of the 5 measure-
ments for each mouse and expressed as g/Kg BW/h.
Microtomography imaging of adipose tissue
Anesthetized mice were placed in the micro-CT scanner
(Bruker - Skyscan 1178). The energy parameters (49 KV;
402 μA; 20 W) were set as previously reported [31]. All
images were obtained in duplicate, in 180°, in gray scale
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and with 84 μm of resolution. The region of interest
(from cervical to tail) was determined according to the
bone projections. Adipose tissue, less dense, is seen in a
darker gray than more dense organs such as muscle,
bone and other abdominals organs. Lung was excluded
of the region of interest in each image. The 2D images
were reconstructed with the NRecon software (Feldkamp
algorithm). Then, images were binarized according to
the established threshold to make adipose tissue show
up in white.
Adipocyte isolation
Adipocytes from fed mice were isolated using modifica-
tions of the established protocol for rat adipocytes [32].
Briefly, perigonadal and subcutaneous fat were cut into
small pieces, and the fragments were digested at 37 °C
with collagenase II (Sigma-Aldrich, St Louis, MO)
(1 mg/ml) in Krebs-Ringer bicarbonate buffer (KRBA)
containing fatty acid free albumin (3 %) and glucose
(6 mM) at pH 7.4. After 45 min of incubation under
continuous shaking, the fat cells were filtered through a
nylon mesh and washed 3 times with KRBA to eliminate
the stroma-vascular fraction and collagenase. The cells
were then counted in a Neubauer`s chamber, and the
viability was verified with trypan blue.
Lipogenesis rates in isolated adipocytes
Isolated adipocytes (106 cells) from fed mice were incu-
bated in triplicate in a Krebs-Ringer phosphate buffer con-
taining 3 % fatty acid-free BSA, 6 mM glucose, 1 mM
acetate and 25 μU human insulin for 2 hours at 37 °C and
saturated with a gas mixture of CO2 (5 %)/O2 (95 %) in a
shaking water bath. All aliquots were incubated with 1 μCi
of 14C-acetate (GE Healthcare-Amersham, United
Kingdom). After incubation, the mixture was acidified
with 0.2 ml H2SO4 (8 N) and incubated for an additional
30 min. Then, the reaction mixture was treated with
2.5 ml of Dole’s reagent (isopropanol: n-heptane: H2SO4,
4:1:0.25, v/v/v) for lipid extraction [33]. Beta radiation in
the lipid extract was counted with scintillation liquid (GE
Healthcare-Amersham, United Kingdom) in a Beckman -
LS 6000TA Beta counter. The results are expressed as the
percentage of the control group.
Lipolysis rates in isolated adipocytes
Glycerol release rates from adipocytes to media were
measured as indicators of lipolysis. The assay was per-
formed in triplicate with Krebs-Ringer phosphate buffer
containing 3 % fatty acid-free BSA and 6 mM glucose,
pH 7.4. Isolated adipocytes (106 cells) from fed mice
were incubated with adenosine deaminase (0.2 U/ml) for
5 min in a shaking water bath at 37 °C to allow for the
degradation of endogenous released adenosine, which is
a potent inhibitor of lipolysis [34]. After this period, cells
were incubated for 1.5 h at 37 °C in the presence or ab-
sence of isoproterenol (10−5 M), a beta-adrenergic recep-
tor agonist. At the end of the incubation, the reaction
was blocked on ice, and cells were carefully removed.
The glycerol content of the incubation medium was
measured using an enzymatic-colorimetric assay (Bio-
clin, Quibasa; Belo Horizonte, Brazil).
In vivo lipolysis
Lipolysis was estimated as glycerol release in response to
isoproterenol stimulation. Fed mice were injected with
isoproterenol (0.3 mg/Kg, ip) [35]. Plasma samples were
collected from the tail tip without anesthesia at basal
time and 15 minutes after isoproterenol ip injection.
The plasma glycerol concentrations were measured
using an enzymatic-colorimetric assay (Bioclin, Quibasa;
Belo Horizonte, Brazil). The lipolysis index is defined as
the ratio between the concentrations of glycerol after
and before isoproterenol stimulus.
Fat tolerance test
Mice underwent an oral fat tolerance test as previously
reported [36]. After an overnight fast, blood samples
were collected before and every 2 hours after the admin-
istration of an oral dose of corn oil (10 ml/Kg of body
weight), during 8 hours. Non-esterified fatty acid (Wako
Chemical, Neuss, Germany) and triglycerides (Chod-Pap;
Roche Diagnostic GmbH, Mannheim, Germany) were de-
termined in plasma by enzymatic-colorimetric methods
according to the manufacturers’ instructions.
Exogenous lipid retention capacity
After 8 hours of fasting, mice received an oral dose of
3H-triolein (5 μCi 3H-TO, GE Healthcare-Amersham,
United Kingdom) mixed with corn oil (180 mg/mouse).
Blood samples were collected 3, 18, 20 and 24 hours to
determine the plasma 3H activity. At 24 hours, mice
were deeply anesthetized and killed by exsanguination.
Liver, gastrocnemius muscle and perigonadal, subcutane-
ous and interscapular brown fat depots were excised and
weighed. Tissue lipids were extracted using the Folch
[37] method, and beta radiation was counted with scin-
tillation liquid (GE Healthcare-Amersham, United King-
dom) in a Beckman - LS 6000TA Beta counter.
RNA extraction and Real time – PCR
Adipose tissue RNA was extracted from 100 mg of tissue
using RNeasy Lipid Tissue Mini Kit (QIAGEN, Germany),
according to the manufacturers’ instructions. The integrity
of the RNA was assessed using Tris-borate 1.2 % agarose
gels stained with ethidium bromide. The amount and pur-
ity of the RNA were determined by optical density read-
ings at 260 and 280 nm (Gene Quant, Amersham-
Pharmacia Biotech). Genomic DNA contamination was
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excluded by running a polymerase chain reaction (PCR)
on the RNA samples. cDNA was prepared from 2 μg of
total RNA by reverse transcription using an Applied Bio-
systems kit (High-Capacity cDNA reverse transcription
kit) according to the manufacturer's instructions. Gene ex-
pression (mRNA) was determined by real-time reverse
transcription polymerase chain reaction (RT-PCR) (Step
One Real-time PCR System, Applied Biosystems, Foster
City, CA, USA) using a SybrGreen PCR master mix. Spe-
cific primers sequences are provided as Additional file 1:
Table S1. Gene expression was quantified using the ΔΔCT
method by measuring the threshold cycle normalized to
β-actin and then expressed relative to the control groups.
Statistical analysis
The results are presented as the mean ± standard error
for the number of determinations (n) indicated. Stu-
dent’s t-test was used for two group comparisons. Statis-
tical significance was defined as p ≤ 0.05.
Results
In a previous study, we reported that apoCIII transgenic
mice accumulated more body fat than control non-
transgenic littermates after consuming a high fat diet
(HFD) for 5 months since weaning [28]. In order to
identify processes that contribute to the development of
obesity in this animal model we investigated apoCIII
transgenic and non-transgenic (NTg) littermate mice
under HFD for 2 month. At first, mice were treated from
2 to 4 months of age, but apoCIII mice adipose depots
were just slightly larger than NTg depots, although
plasma leptin levels and adipose exogenous lipid retention
capacity were significantly elevated (Additional file 1:
Figure S1). Aditional groups of mice were treated with
HFD from 4 to 6 months of age, and in this treatment,
apoCIII mice were significantly more obese than NTg
(Fig. 1). Thus, this protocol was used for further experi-
ments to understand the mechanisms responsible for this
HFD effect on apoCIII mice.
The HFD did not change the apoCIII hyperlipidemic
phenotype that is already present under a low fat diet
(Table 1). The apoCIII mice maintained higher plasma
levels of triglycerides (~5-fold), cholesterol (~70 %) and
non-esterified fatty acids (NEFA, ~100 %) when com-
pared to NTg mice. Glycerol plasma levels did not differ
in the fasting state but were higher in apoCIII than in
NTg mice in the fed state. This key finding indicates that
the higher glycerol levels in fed CIII mice are derived
from the intravascular lipolysis of post-prandial plasma
lipoproteins and do not reflect adipose tissue lipolysis
(fasting). Fasted and fed glycemia levels were similar in
both groups (Table 1), as well as the glucose tolerance to
an oral glucose load (data not shown).
After 2 months on a HFD diet, apoCIII mice showed
greater body weight gain compared to NTg controls
(Fig. 1a and b), although there were no significant differ-
ences in final whole body weight. Food intake (Fig. 1c)
and resting metabolism (CO2 production, Fig. 1d) were
similar between groups. However, apoCIII mice devel-
oped larger adipose tissue depots than NTg controls
(Fig. 1e). The mass of the perigonadal and subcutaneous
fat depots of apoCIII mice were 49 and 36 % greater
than the respective NTg mice depots. Confirming in-
creased adiposity, the leptin plasma levels in apoCIII
were two-fold higher than in NTg mice (Fig. 1f ). Micro-
CT scanner representative images (Fig. 1g) illustrate the
enhanced subcutaneous and visceral adiposity in apoCIII
mice.
De novo lipogenesis rates were compared in isolated
adipocytes from apoCIII and NTg mice (Fig. 2). There
were no significant differences in de novo lipid synthesis
in adipocytes from the perigonadal adipose tissue of
both groups of mice. Lipogenesis rates in the subcutane-
ous adipose tissue was actually decreased by 25 % in
apoCIII compared to control NTg mice. Thus, this
(See figure on previous page.)
Fig. 1 ApoCIII transgenic (Tg) mice accumulate more body fat compared with non-transgenic (NTg) mice after 8 weeks of high fat diet. Body
weight (a), weight gain (b) (n = 6-7), daily food intake (c), resting metabolism (d) (n = 4), relative weight of adipose tissue depots (e) (n = 6-7) and
plasma leptin levels (f) (n = 13). Mean ± SE. Student’s t test, * P < 0.05 and # P < 0.07. Representative tomography images (g): The less dense adipose
tissue appears as darker gray than more dense organs such as muscle, bone and others (middle images). Lung was excluded of the region of interest
in each image (upper right images). The images were binarized accordantly to the established threshold to make adipose tissue show up in white
(right images)
Table 1 Plasma levels of lipids and glucose in non-transgenic
(NTg) and apoCIII transgenic mice after 8 weeks of high fat diet.
NTg CIII
CHOL (mg/dL) Fed 171 ± 11.3 (6) 288 ± 36.7** (7)
TG (mg/dL) Fast 60 ± 6.9 (4) 284 ± 51.7** (4)
Fed 52 ± 5.6 (6) 341 ± 54.4** (7)
NEFA (nmol/L) Fast 0.69 ± 0.15 (4) 0.97 ± 0.16 (4)
Fed 0.7 ± 0.06 (6) 1.3 ± 0.04** (7)
Glycerol (mg/dL) Fast 3.7 ± 0.3 (15) 4.1 ± 0.3 (13)
Fed 3.2 ± 0.3 (15) 4.6 ± 0.4* (13)
GLUC (mg/dL) Fast 102.4 ± 4.8 (13) 107.6 ± 3.6 (15)
Fed 107.6 ± 3.6 (13) 114.8 ± 3.6 (15)
Triacylglycerol (TG), Cholesterol (CHOL) and Non-esterified fatty acid (NEFA).
Mean ± SE (n). Student’s t test, *P ≤ 0.05 **P ≤ 0.01 for CIII vs NTg
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process certainly does not explain the enlargement of
this adipose depot.
Next, lipolysis rates were measured in vitro (in isolated
adipocytes) and in vivo. Basal and isoproterenol-
stimulated lipolysis in isolated adipocytes from perigona-
dal and subcutaneous fat depots are shown in Fig. 3a.
Lipolysis was determined as glycerol release to the
media. Basal lipolysis in subcutaneous adipocytes was
significantly reduced by 55 % in apoCIII compared to
NTg adipocytes, but no differences were noted in peri-
gonadal adipocytes. When lipolysis was maximally stim-
ulated by isoproterenol in vitro, no significant
differences were observed between adipocytes of both
groups of mice. Therefore, the marked reduction in sub-
cutaneous lipolysis may explain increased mass of this
adipose depot observed in apoCIII mice (Fig. 1e). To
confirm and expand these results in a more physiological
context, we also estimated adipose lipolysis rates in vivo,
by measuring plasma glycerol levels after isoproterenol
injection, which stimulates adipose tissue hormone sen-
sitive lipase. Because basal glycerol plasma levels in fed
apoCIII mice are higher, the response to isoproterenol
Fig. 2 Lipogenesis rates measured in isolated adipocytes from
adipose tissues in apoCIII transgenic (Tg) and non-transgenic (NTg)
mice after 8 weeks of high fat diet. Adipocytes (106 cells) were
incubated for 2 hours at 37°C in the presence of 1 μCi 14C-acetate,
10 nM acetate, 25 μU insulin, and 6 mM glucose. Mean ± SE (n = 9)
(three independent experiments)
Fig. 3 Lipolysis rates (in the basal and isoproterenol-stimulated conditions) of apoCIII transgenic (Tg) and non-transgenic (NTg) mice after 8 weeks
of high fat diet measured in isolated adipocytes (a-b) (n = 6, two independent experiments) and in vivo (c-e) (n = 13-15). Adipocytes (106) isolated
from fed mice were incubated for 1.5 hours at 37°C in the presence of 0.2 U/ml adenosine deaminase, with or without 10−5 M isoproterenol.
Lipolysis index in fed mice is estimated as the ratio of glycerol plasma levels in the isoproterenol-stimulated over basal conditions. Mean ± SE.
Student’s t test, *P ≤ 0.05; **P ≤ 0.01
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stimulation in vivo must be normalized by the basal
levels of glycerol (Fig. 3c). Therefore, the in vivo lipolysis
index is expressed as the ratio between glycerol concen-
trations in the stimulated and basal states. It is verified
that the isoproterenol lipolytic response is significantly
reduced by approximately 30 % in apoCIII transgenic
mice (Fig. 3e). The possible reduction of plasma lipopro-
tein lipase (LPL) amount is not implicated in this result,
since plasma LPL activities (measured with exogenous
substrate) were similar in both groups (Table 2).
In order to understand whether apoCIII would alter
the response to fat intake, a fat tolerance test was per-
formed. Increases in TG and NEFA plasma levels after
the fat load are shown as absolute and relative plasma
values (Fig. 4a-d). The similarities in curves slopes up to
2 hours indicate that fat absorption rates are similar be-
tween both groups, regardless the basal plasma TG
levels. However, 4 hours after the oral oil dose, plasma
TG reduces rapidly in the NTg group, but not in the
apoCIII group, which characterizes the delay in TG-rich
lipoproteins clearance caused by the apoCIII overexpres-
sion. It is important to mention that under HFD there is
no alteration of TG liver production rates in control and
apoCIII mice [38]. After 8 hours, TG plasma levels re-
turn to their respective basal levels in both groups. The
NEFA curves (Fig. 4c) indicate a greater availability of
these substrates during the post-prandial state, from 2 to
6 hours after the oil dose, in the apoCIII mice plasma
compartment. Interestingly, we found higher expression
of FATP1 and CD36 mRNA, both associated with fatty
acid uptake in the adipose depots of apoCIII mice
(Fig. 5). Regarding genes related to adipose tissue lipoly-
sis, there were no differences in adipose tissue ATGL
(adipose triglyceride lipase), beta 3-adrenergic receptors,
perilipin and LPL mRNA levels between groups (Fig. 5).
To evaluate adipose tissue capacity to take up and re-
tain lipids, mice were challenged with an oral dose of
corn oil containing the tracer 3H-triolein. The time
course of plasma radioactivity and tissue retention after
24 hours are shown in Fig. 6. Like already observed in
the fat tolerance test, there is a delay in the exogenous
TG plasma clearance in apoCIII mice, observed as an in-
crease in their plasma levels of 3H-TG after 3 hours,
which was normalized at 18 and 20 hours and decreased
at 24 hours (Fig. 6a). At this time point (24 hours), tis-
sues were collected and the lipid extraction data demon-
strates a higher retention of the TG tracer in the
perigonadal and brown adipose tissues of apoCIII mice
(Fig. 6b).
Discussion
In this work we examined the potential principal mecha-
nisms involved in the increased adiposity in response to
five months of high fat diet in mice overexpressing
apoCIII [28]. We confirmed the previous observed
apoCIII fatter phenotype even in a shorter (2 months)
period of high fat diet. The food ingestion and body en-
ergy expenditure cannot explain this enlarged body fat
mass, since these processes were similar in apoCIII and
NTg mice. However, the weight gain, mass of adipose
tissues and leptin plasma levels were significantly greater
in apoCIII mice. The results show that this exacerbated
HFD response in apoCIII mice can be explained by an
increased exogenous (diet) lipid retention capacity in
adipose tissue and reduced adipose lipolysis rates in
apoCIII mice. Lipid deposition in non-adipose tissues
seems not to occur in these mice, since lipid retention in
liver and skeletal muscle were similar to control NTg
mice, at least in this relatively short time of HFD. There-
fore, data presented here demonstrate that apoCIII over-
expression favors an increased lipid retention (balance
between uptake and lipolysis) in adipose depots. We
propose that this is an adaptation to the marked greater
availability of post-prandial NEFA derived from long
lasting circulating TG rich lipoproteins that are taken up
and stored by the adipose tissues.
Previous studies (reviewed in ref [39]) showed that
modulation of LPL activity through its activators [9, 10]
or inhibitors [14, 15] may have effects on triglyceride
storage. For instance, LPL deficiency in adipose tissue
reduced adiposity in obese mice [40], while its overex-
pression in muscle resulted in increased TG content in
this tissue [41, 42]. In addition, apoCI transgenic mice
present lower LPL activity and are protected against
obesity [15]. On the contrary, we show here (Table 2)
and elsewhere [43] that apoCIII overexpression does not
change plasma LPL activities and still results in diet in-
duced obesity. Nowadays, it has become clear that apoC-
III inhibition of LPL requires a very high CIII/CII ratio,
which is not found in vivo [26]. Indeed, Aalto-Settala et
al. [22] showed that VLDL from apoCIII and NTg mice
are equally hydrolyzed in vitro by purified LPL. Accord-
ingly, the higher glycerol and NEFA post-prandial
plasma levels in apoCIII mice (Table 1, Fig. 4) indicate
no inhibition of plasma TG rich lipoprotein lipolysis. If
LPL were inhibited in apoCIII mice, the availability of
NEFA to adipose tissues would be severely limited and
Table 2 Plasma lipoprotein lipase (LPL) activity in non-
transgenic (NTg) and apoCIII transgenic mice.
NTg CIII
Chow diet Fed 44 ± 2.4 (4) 37 ± 0.9 (5)
Fed/post-heparin 51 ± 3.0 (4) 38 ± 1.2 (5)
HFD Fed 40 ± 2.4 (4) 35 ± 5.4 (4)
Chow diet from weaning to 6 month of age and HFD (high fat diet) from 4 to
6 month of age. Plasma obtained in fed state before and after heparin ip
injection (100 U/Kg BW). Mean ± SE (n). Student’s t test: no differences
between groups
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increased adiposity would not occur as shown here
(Fig. 1) and previously [28]. Therefore, we rule out a role
of LPL to explain increased obesity in apoCIII mice. In-
stead, the higher substrate availability (Fig. 4), lower adi-
pose lipolysis (Fig. 3) and higher adipose tissue uptake/
retention capacity (Fig. 6) are the key factors implicated
in the diet induced obesity in apoCIII mice.
The detailed molecular pathways underlying the in-
duction of fat accumulation by overexpression of
apoCIII were not addressed in this study. It is well
known that fatty acids can modulate intracellular signal-
ing pathways by changing cell membrane fluidity, the
composition of lipid rafts and second messengers pro-
duction. In addition, they can act on receptors either in
the cell membrane or in the nucleus, such as the toll-
like receptors (TLRs) and the peroxisome-proliferator-
activated receptors (PPARs), respectively. We propose
that apoCIII induced high NEFA availability could
Fig. 4 Plasma levels of triglycerides (TG, a and b) and non-esterified fatty acid (NEFA, c and d) after an oral fat load (corn oil 10 ml/Kg bw) administered
to fasted apoCIII transgenic (Tg) and non-transgenic (NTg) mice that had been on a high fat diet for 8 weeks. Absolute (a, c) and incremental values
(b, d). Mean ± SE (n= 4). Student’s t test, * p≤ 0.05
Fig. 5 Adipose tissue mRNA expression of genes related to fatty acid uptake and lipolysis in apoCIII transgenic (Tg) and non-transgenic (NTg)
mice after 8 weeks of high fat diet. Relative values normalized by β-actin mRNA. Mean ± SE (n = 7-9). Student’s t test, *p≤ 0.05. ATGL (adipose
triglyceride lipase), CD36/FAT (fatty acid translocase), FATP1 (fatty acid transport protein-1), UCP1 (uncoupling protein-1), B3AR (beta 3 adrenergic
receptor), FABPpm (fatty acid binding protein- plasma membrane)
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modulate specific protein activities or gene expression
related to lipid uptake, accumulation and lipolysis in the
adipose tissue of apoCIII mice. In fact, the adipose tissue
FATP1 and CD36 expression were higher in apoCIII
mice, suggesting that fatty acid uptake may be increased
in these mice. Other effects on lipid accumulation and
intracellular lipolysis observed here might be the result
of direct modulation of key proteins activity, without
modifying necessarily the gene expression. For instance,
those triggered by isoproterenol stimulation of intracel-
lular lipolysis, which are mediated by the B3R-AMPc-
PKA-HSL pathway [44]. In addition, it has been sug-
gested that apoCIII per se, independently of TG/NEFA
levels, stimulates inflammatory processes in the vascula-
ture [20, 45]. Thus, one could speculate that apoCIII in-
duced inflammation may have hampered tissue lipolysis
and facilitated lipid accumulation in adipocytes.
Conclusion
Together the results indicate that apoCIII overexpres-
sion exacerbates diet-induced obesity by promoting in-
creased availability of NEFA from post-prandial TG-rich
lipoproteins combined with greater adipose capacity for
lipid uptake and retention and reduced adipose lipolysis.
Therefore, this study revealed a new risk factor for sus-
ceptibility to obesity that can be attributed to high levels
of apoCIII on top of those already reported for athero-
sclerosis and vasculature inflammation.
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